[Taylor&Francis] Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes

mhamzabashir Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-11-04 05:44
Reward30points

journalㄩExpert Review of Anticancer Therapy

AuthorsㄩCaner Acar; Haydar aatay Y邦ksel; Gkhan ahin; Fatma Pinar Aar; Burak Karaca

Published dateㄩ2025-8-3

DOIㄩ10.1080/14737140.2025.2517274

PDF linkㄩhttps://www.tandfonline.com/doi/pdf/10.1080/14737140.2025.2517274

Article linkㄩhttps://doi.org/10.1080/14737140.2025.2517274

Article SourceㄩInforma UK Limited﹝


Remarkㄩ
Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Senior Member
  • post

  • reply

  • points

    1110


Return to the list